EVT 101

DRUG2 trials

Sponsors

Evotec Neurosciences GmbH, Janssen Research & Development, LLC

Conditions

DepressionHuman Volunteers

Phase 1

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function

CompletedNCT00526968

Evotec Neurosciences GmbHHuman Volunteers

Start: 2007-09-30End: 2007-12-31Updated: 2008-02-18

Phase 2

Safety and Efficacy of EVT 101 in Treatment-Resistant Depression

TerminatedNCT01128452

Janssen Research & Development, LLCDepression

Start: 2010-06-30End: 2011-03-31Updated: 2016-03-28